Farther Finance Advisors’s Theravance Biopharma TBPH Stock Holding History

Farther Finance Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$850	Sell	50 -4	-7%	-$66	﹤0.01%	5416
2026 Q1	$855	Buy	54 +1	+2%	+$18	﹤0.01%	5147
2025 Q4	$992	Sell	53 -25	-32%	-$415	﹤0.01%	4913
2025 Q3	$1.14K	Buy	78 +55	+239%	+$695	﹤0.01%	4331
2025 Q2	$254	Hold	23	–	–	﹤0.01%	4167
2025 Q1	$207	Hold	23	–	–	﹤0.01%	3949
2024 Q4	$216	Hold	23	–	–	﹤0.01%	3642
2024 Q3	$185	Hold	23	–	–	﹤0.01%	3670
2024 Q2	$196	Hold	23	–	–	﹤0.01%	3499
2024 Q1	$208	Sell	23 -4	-15%	-$37	﹤0.01%	3265
2023 Q4	$303	Hold	27	–	–	﹤0.01%	3128
2023 Q3	$233	Buy	+27	New	+$261	﹤0.01%	2441

Other funds holding TBPH

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

SSA

Sierra Summit Advisors Incline Village, Nevada $895M AUM 106% 1-Year Est. Return

JWS

Juncture Wealth Strategies Scottsdale, Arizona $384M AUM 27.62% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

TIM

Thompson Investment Management Madison, Wisconsin $872M AUM 35.59% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Farther Finance Advisors's TBPH Position: Q2 2026 in Review

Farther Finance Advisors reduced its Theravance Biopharma (TBPH) stake by 7.4% in Q2 2026, selling an estimated $66 and leaving 50 shares worth $850. The position accounts for ﹤0.01% of the portfolio, ranked #5416.

Farther Finance Advisors first reported a position in TBPH in Q3 2023 and has held it in 12 quarters since. The position peaked at $1.14K in Q3 2025. 18 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

Farther Finance Advisors held 50 shares of Theravance Biopharma worth $850 as of Q2 2026.
Farther Finance Advisors sold 4 Theravance Biopharma shares in Q2 2026, an estimated $66.
Theravance Biopharma made up ﹤0.01% of Farther Finance Advisors's portfolio in Q2 2026, its #5416 holding.
Farther Finance Advisors first reported a position in Theravance Biopharma in Q3 2023 and has held it in 12 quarters since.
Farther Finance Advisors's Theravance Biopharma position peaked at $1.14K in Q3 2025.
18 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Farther Finance Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.